Cardiorenal risk-based management in T2DM: the latest standard of care
Seminar
•
AstraZeneca
About the CPD course
This slide deck covers the impact of T2DM on the cardiorenal system and cardiorenal protection offered with specific treatment. It also discusses the opportunities available in primary care using a risk-based approach in the management of T2DM and how to initiate current treatment options in patients.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.